Reverse the Resistance to PARP Inhibitors

被引:67
|
作者
Kim, Yevgeniy [1 ]
Kim, Aleksei [1 ]
Sharip, Ainur [1 ]
Sharip, Aigul [1 ]
Jiang, Juhong [2 ]
Yang, Qing [1 ]
Xie, Yingqiu [1 ]
机构
[1] Nazarbayev Univ, Sch Sci & Technol, Dept Biol, 53 Kabanbay Batyr Ave, Astana 010000, Kazakhstan
[2] Guangzhou Med Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Guangdong, Peoples R China
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2017年 / 13卷 / 02期
基金
中国国家自然科学基金;
关键词
PARP; PARP inhibitor; drug resistance; DNA repair; STRAND-BREAK REPAIR; SHOCK-PROTEIN; 90; HOMOLOGOUS RECOMBINATION; DNA-REPAIR; SECONDARY MUTATIONS; SYNTHETIC LETHALITY; MILD HYPERTHERMIA; TUMOR SUPPRESSION; CANCER-CELLS; BRCA1;
D O I
10.7150/ijbs.17240
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the DNA repair machineries is activated by Poly ( ADP- ribose) Polymerase ( PARP) enzyme. Particularly, this enzyme is involved in repair of damages to single- strand DNA, thus decreasing the chances of generating double- strand breaks in the genome. Therefore, the concept to block PARP enzymes by PARP inhibitor ( PARPi) was appreciated in cancer treatment. PARPi has been designed and tested for many years and became a potential supplement for the conventional chemotherapy. However, increasing evidence indicates the appearance of the resistance to this treatment. Specifically, cancer cells may acquire new mutations or events that overcome the positive effect of these drugs. This paper describes several molecular mechanisms of PARPi resistance which were reported most recently, and summarizes some strategies to reverse this type of drug resistance.
引用
收藏
页码:198 / 208
页数:11
相关论文
共 50 条
  • [1] Resistance to PARP-inhibitors in cancer therapy
    Montoni, Alicia
    Robu, Mihaela
    Pouliot, Emilie
    Shah, Girish M.
    FRONTIERS IN PHARMACOLOGY, 2013, 4
  • [2] A review on mechanisms of resistance to PARP inhibitors
    Desai, Chirag
    Pathak, Anand
    Limaye, Sewanti
    Maniar, Vashishth
    Joshi, Archita
    INDIAN JOURNAL OF CANCER, 2022, 59 : S119 - S129
  • [3] Successes and challenges of PARP inhibitors in cancer therapy
    Ricks, Tiffany K.
    Chiu, Haw-Jyh
    Ison, Gwynn
    Kim, Geoffrey
    Mckee, Amy E.
    Kluetz, Paul
    Pazdur, Richard
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [4] Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
    Lim, Joline S. J.
    Tan, David S. P.
    CANCERS, 2017, 9 (08)
  • [5] PARP Inhibitors for the Treatment of Ovarian Cancer
    Cortesi, Laura
    Toss, Angela
    Cucinotto, Iole
    CURRENT CANCER DRUG TARGETS, 2018, 18 (09) : 877 - 893
  • [6] Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
    Chalmers, Anthony J.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (07) : 520 - 533
  • [7] "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors
    Incorvaia, Lorena
    Passiglia, Francesc
    Rizzo, Sergio
    Galvano, Antonio
    Listi, Angela
    Barraco, Nadia
    Maragliano, Rossella
    Calo, Valentina
    Natoli, Clara
    Ciaccio, Marcello
    Bazan, Viviana
    Russo, Antonio
    ONCOTARGET, 2017, 8 (14) : 23891 - 23904
  • [8] Advances and perspectives of PARP inhibitors
    Yi, Ming
    Dong, Bing
    Qin, Shuang
    Chu, Qian
    Wu, Kongming
    Luo, Suxia
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (01)
  • [9] A snapshot of chemoresistance to PARP inhibitors
    Chiarugi, Alberto
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (01) : 42 - 48
  • [10] PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
    Rose, Maddison
    Burgess, Joshua T.
    O'Byrne, Kenneth
    Richard, Derek J.
    Bolderson, Emma
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8